

*The National Academies of*  
SCIENCES • ENGINEERING • MEDICINE

BOARD ON GLOBAL HEALTH  
FORUM ON PUBLIC-PRIVATE PARTNERSHIPS FOR GLOBAL HEALTH AND SAFETY

The following table was provided to workshop participants as background material for the workshop session on “Lessons Learned from Development, Iterative Improvement, and Reform of Public-Private Partnerships and their Governance.” The document was drafted by forum staff and finalized with input from session panelists. The purpose of the table was to provide participants more detailed background information on each partnership presented during this session.

Operating Years	Target Country/ Region	Partners	Focus	Partnership Goal	Governance Structure (publicly available)	Documented Partnership Outcomes/Impacts
-----------------	------------------------	----------	-------	------------------	---	---

<b>ACCESS ACCELERATED</b>	2017-ongoing	Worldwide	Initial Sponsors: 23 pharmaceutical companies and associations: Almirall, Astellas, Bayer, Bristol-Myers Squibb, Celgene, Chugai, Daiichi Sankyo, Eisai, Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson, Menarini, Merck, MSD, Novartis, Pfizer, Roche, Sanofi, Shionogi, Shire, Sumitomo Dainippon, Takeda, UCB, and The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), BIO, EFPIA, JPMA, and PhRMA Partners: The World Bank, Union for International Cancer Control (UICC)	moving NCD care forward: access to NCD prevention and care	To support the United Nations Sustainable Development Goal to reduce premature deaths from NCDs by one-third by 2030.	<a href="http://www.accessaccelerated.org/">http://www.accessaccelerated.org/</a>  <a href="http://www.accessaccelerated.org/initiatives/">http://www.accessaccelerated.org/initiatives/</a>
	<b>DREAMS</b>	2014-ongoing	Sub-Saharan Africa; Haiti  (Botswana, Cote D'Ivoire, Kenya, Lesotho, Malawi, Mozambique, Namibia, Rwanda, South Africa, Swaziland, Tanzania, Uganda, Zambia, Zimbabwe)	U.S. President's Emergency Plan for AIDS Relief (PEPFAR); the Bill & Melinda Gates Foundation; Girl Effect; Johnson & Johnson; Gilead Sciences; ViiV Healthcare	prevention among adolescent girls and young women	To reduce HIV infections by 40 percent among adolescent girls and young women in 10 sub-Saharan African countries by 2017.  Country-specific targets: <a href="https://www.pepfar.gov/partnerships/ppp/dreams/c69041.htm">https://www.pepfar.gov/partnerships/ppp/dreams/c69041.htm</a>

SESSION IV. LESSONS LEARNED FROM DEVELOPMENT, ITERATIVE IMPROVEMENT, AND REFORM OF PUBLIC-PRIVATE PARTNERSHIPS AND THEIR GOVERNANCE

Operating Years	Target Country/ Region	Partners	Focus	Partnership Goal	Governance Structure (publicly available)	Documented Partnership Outcomes/Impacts
-----------------	------------------------	----------	-------	------------------	---	---

<b>GHIT FUND</b>	2013-ongoing	Worldwide	<p><u>Full partners:</u> Japanese Ministry of Foreign Affairs; the Japanese Ministry of Health, Labour and Welfare; UNDP; Astellas; Daiichi Sankyo Company; Eisai Company; Shionogi &amp; Co.; Takeda; Gates Foundation; Wellcome Trust; Chugai Pharmaceutical Co.; Eisai Co.; Fujifilm; Shionogi</p> <p><u>Associate partners:</u> Otsuka Pharmaceutical Co.; Sysmex</p> <p><u>Affiliate partners:</u> GlaxoSmithKline; Johnson &amp; Johnson; Kyowa Kirin; Merck; Mitsubishi Tanabe Pharma; Nipro; Sumitomo Dainippon Pharma;</p>	research; product development	To facilitate international partnerships that bring Japanese innovation, investment, and leadership to the global fight against infectious diseases and poverty in the developing world.	<p><a href="https://www.ghitfund.org/about/governance/leadership">https://www.ghitfund.org/about/governance/leadership</a></p> <p><a href="https://www.forbes.com/sites/medidata/2015/04/30/investing-in-drugs-that-wont-make-money/#1024b2c83bb6">https://www.forbes.com/sites/medidata/2015/04/30/investing-in-drugs-that-wont-make-money/#1024b2c83bb6</a> (2015)</p> <p><a href="http://www.thelancet.com/journals/langlo/article/PIIS2214-109X(13)70055-X/abstract">http://www.thelancet.com/journals/langlo/article/PIIS2214-109X(13)70055-X/abstract</a> (2013)</p> <p><a href="http://www.nature.com/nmjournal/v19/n12/full/nm1213-1553.html">http://www.nature.com/nmjournal/v19/n12/full/nm1213-1553.html</a> (2013)</p>	<p><a href="https://ghitfund.org/impact/impact">https://ghitfund.org/impact/impact</a></p> <p><a href="http://5th.ghitfund.org/replenishment/en">http://5th.ghitfund.org/replenishment/en</a> (2017)</p> <p><a href="https://www.ghitfund.org/general/annualreport">https://www.ghitfund.org/general/annualreport</a> (2016)</p>
<b>AVAHAN</b>	2003-ongoing	India (Andhra Pradesh, Karnataka, Maharashtra, Tamil Nadu, Manipur, Nagaland)	Bill and Melinda Gates Foundation; Lead implementing partners; Capacity building partners; Other supporting partners; Monitoring and evaluation partners; Knowledge building partners	prevention education and service	To reduce HIV transmission and lower the prevalence of sexually transmitted infections in vulnerable high-risk populations – female sex workers (FSWs), men who have sex with men (MSM), transgenders, people who inject drugs (PWID) – through prevention education and services.	<p><a href="http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0136177">http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0136177</a> (2015)</p> <p><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3287554/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3287554/</a> (2011)</p> <p><a href="http://scholarworks.gvsu.edu/cgi/viewcontent.cgi?article=1027&amp;context=spnareview">http://scholarworks.gvsu.edu/cgi/viewcontent.cgi?article=1027&amp;context=spnareview</a> (2009)</p> <p><a href="https://docs.gatesfoundation.org/documents/avahan_hivprevention.pdf">https://docs.gatesfoundation.org/documents/avahan_hivprevention.pdf</a> (2008)</p>	<p><a href="http://www.thelancet.com/journals/langlo/article/PIIS2214-109X(13)70083-4/fulltext">http://www.thelancet.com/journals/langlo/article/PIIS2214-109X(13)70083-4/fulltext</a> (2013)</p> <p><a href="http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)61390-1/abstract">http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)61390-1/abstract</a> (2011)</p> <p><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3287556/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3287556/</a> (2011)</p> <p><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3287555/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3287555/</a> (2011)</p> <p><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3287553/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3287553/</a> (2011)</p> <p><a href="https://docs.gatesfoundation.org/documents/avahan_hivprevention.pdf">https://docs.gatesfoundation.org/documents/avahan_hivprevention.pdf</a> (2008)</p>

Operating Years	Target Country/ Region	Partners	Focus	Partnership Goal	Governance Structure (publicly available)	Documented Partnership Outcomes/Impacts
-----------------	------------------------	----------	-------	------------------	---	---

ACHAP	2000-2014 <sup>1</sup>	Botswana	Merck & Co., Inc.; the Merck Foundation; the Bill & Melinda Gates Foundation; and the Government of Botswana	prevention; care; treatment; capacity-building; systems strengthening	To prevent and treat HIV/AIDS in Botswana. ACHAP, established in July 2000, supported the goals of the Government of Botswana to decrease HIV incidence and significantly increase the rate of diagnosis and the treatment of the disease, by rapidly advancing prevention programs, healthcare access, patient management and treatment of HIV/AIDS.	<a href="http://web.archive.org/web/20030322045745/http://www.achap.org:80/">http://web.archive.org/web/20030322045745/http://www.achap.org:80/</a> <a href="http://www.fsg.org/publications/adapting-through-crisis#download-area">http://www.fsg.org/publications/adapting-through-crisis#download-area</a> (2014) <a href="http://www.msdrresponsibility.com/wp-content/uploads/pdfs/key-initiatives_access-to-health_african-comprehensive-hiv-aids-partnerships.pdf">http://www.msdrresponsibility.com/wp-content/uploads/pdfs/key-initiatives_access-to-health_african-comprehensive-hiv-aids-partnerships.pdf</a> (2014) <a href="http://www.achap.org/annual.php">http://www.achap.org/annual.php</a> (2014, 2013, 2012) <a href="https://www.cgdev.org/sites/default/files/archive/doc/events/6.06.07/ACHAP_Presentation_June_6_Event.pdf">https://www.cgdev.org/sites/default/files/archive/doc/events/6.06.07/ACHAP_Presentation_June_6_Event.pdf</a> (2007) <a href="http://digitalcommons.law.yale.edu/cgi/viewcontent.cgi?article=1080&amp;context=yjhple">http://digitalcommons.law.yale.edu/cgi/viewcontent.cgi?article=1080&amp;context=yjhple</a> (2004)
-------	------------------------	----------	--	---	---	---

<sup>1</sup> The original ACHAP partnership ended in 2014. Today, ACHAP operates as an independent entity with a broader health mandate and wider geographical focus continuing to build on and leverage its core competencies in the field of HIV/AIDS and related health conditions. Its goal is to provide comprehensive, innovative and catalytic solutions through Public Private Community Partnerships (PPCP) to achieve sustainable population health. More information can be found here <http://www.achap.org/index.php>.